Lund, Sweden, 4 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) , a biotechnology company developing tumor-directed immunotherapies, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held 8-10 January, 2018 in San Francisco, US.
Chief Executive Officer Per Norlén will give an update on the company’s clinical stage project ADC-1013, out-licensed to Janssen Biotech Inc., as well as the near-clinical bispecific antibody ATOR-1015 and the preclinical projects ALG.APV-527 and ATOR-1017.
The presentation will take place on 8 January, at 10:30 a.m. PST /8 Jan 7:30 p.m. CET. The audio and slide presentation will be webcasted live and can be accessed via the Alligator web site. To access the presentation, live and replay, please g o to https://event.webcasts.com/starthere.jsp?ei=1175723&tp_key=101995f0f8 .
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: [email protected] .
The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on 4 January 2018.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immunotherapies. Alligator’s growing pipeline includes four lead clinical and pre-clinical therapeutic antibodies (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visi t www.alligatorbioscience.com .
Powered by WPeMatico
